Boston Scientific Analysts Update Ratings and Targets

Several brokerages have revised their recommendations and price targets for the medical device company.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Boston Scientific (NYSE: BSX), a major medical device manufacturer, has seen several updates to analyst ratings and price targets in recent weeks. Wall Street Zen downgraded the stock from 'buy' to 'hold' on February 7th, while Sanford C. Bernstein reaffirmed an 'outperform' rating. Additionally, Boston Scientific executives have disclosed insider stock transactions, including the sale of over 17,000 shares by an executive vice president and 160,000 shares by the CEO.

Why it matters

Analyst ratings and price targets are closely watched by investors as they can significantly impact a company's stock price. Insider transactions also provide insight into management's views on the company's prospects. These updates on Boston Scientific are relevant to investors tracking the medical device industry and the company's performance.

The details

The analyst rating changes and insider transactions involve Boston Scientific's core business activities, including product development, clinical research, regulatory affairs, and commercial sales. The stock sales by executives represent a decrease in their ownership positions.

  • On February 7, 2026, Wall Street Zen downgraded Boston Scientific from 'buy' to 'hold'.
  • On February 6, 2026, Sanford C. Bernstein reaffirmed an 'outperform' rating on Boston Scientific.
  • On December 1, 2025, Boston Scientific EVP Arthur C. Butcher sold 17,313 shares.
  • On February 2, 2026, Boston Scientific CEO Michael F. Mahoney sold 160,901 shares.

The players

Wall Street Zen

An investment research firm that downgraded Boston Scientific's stock rating.

Sanford C. Bernstein

An investment research firm that reaffirmed an 'outperform' rating on Boston Scientific's stock.

Arthur C. Butcher

The executive vice president of Boston Scientific who sold 17,313 shares.

Michael F. Mahoney

The CEO of Boston Scientific who sold 160,901 shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.